MX2023001140A - Uso del dexpramipexol para el tratamiento de asma moderado a grave. - Google Patents

Uso del dexpramipexol para el tratamiento de asma moderado a grave.

Info

Publication number
MX2023001140A
MX2023001140A MX2023001140A MX2023001140A MX2023001140A MX 2023001140 A MX2023001140 A MX 2023001140A MX 2023001140 A MX2023001140 A MX 2023001140A MX 2023001140 A MX2023001140 A MX 2023001140A MX 2023001140 A MX2023001140 A MX 2023001140A
Authority
MX
Mexico
Prior art keywords
dexpramipexole
severe asthma
moderate
treatment
need
Prior art date
Application number
MX2023001140A
Other languages
English (en)
Spanish (es)
Inventor
Calman Philip Prussin
Original Assignee
Areteia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Areteia Therapeutics Inc filed Critical Areteia Therapeutics Inc
Publication of MX2023001140A publication Critical patent/MX2023001140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023001140A 2020-08-05 2021-08-05 Uso del dexpramipexol para el tratamiento de asma moderado a grave. MX2023001140A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063061226P 2020-08-05 2020-08-05
US202163136933P 2021-01-13 2021-01-13
US202163147024P 2021-02-08 2021-02-08
US202163174938P 2021-04-14 2021-04-14
PCT/US2021/044719 WO2022031956A1 (en) 2020-08-05 2021-08-05 Use of dexpramipexole for the treatment of moderate to severe asthma

Publications (1)

Publication Number Publication Date
MX2023001140A true MX2023001140A (es) 2023-05-18

Family

ID=80115688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001140A MX2023001140A (es) 2020-08-05 2021-08-05 Uso del dexpramipexol para el tratamiento de asma moderado a grave.

Country Status (11)

Country Link
US (4) US20220040154A1 (https=)
EP (1) EP4192453A4 (https=)
JP (1) JP2023538278A (https=)
KR (1) KR20230067604A (https=)
CN (1) CN116419746A (https=)
AU (1) AU2021322255A1 (https=)
CA (1) CA3186844A1 (https=)
CL (1) CL2023000296A1 (https=)
IL (1) IL300357A (https=)
MX (1) MX2023001140A (https=)
WO (1) WO2022031956A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260119B (zh) * 2022-07-26 2023-02-10 山东京卫制药有限公司 一种普拉克索昔萘酸盐及其药物缓释制剂
KR20250001767A (ko) 2023-06-29 2025-01-07 재단법인 아산사회복지재단 천식의 분류를 위한 바이오마커 및 이의 용도
WO2025137498A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Matrix tablets of dexpramipexole and methods of manufacturing and use thereof
US20250205206A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
WO2025240942A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1730129B1 (en) * 2004-03-19 2011-01-19 Dipharma Francis S.r.l. Intermediates for the preparation of pramipexole
WO2009120927A2 (en) * 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
WO2013034173A1 (en) * 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
EP3838271B1 (en) * 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) * 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2017197360A1 (en) * 2016-05-13 2017-11-16 The Regents Of The University Of California Airway mucus impaction

Also Published As

Publication number Publication date
EP4192453A4 (en) 2024-11-13
US20220040154A1 (en) 2022-02-10
CA3186844A1 (en) 2022-02-10
US20240041841A1 (en) 2024-02-08
EP4192453A1 (en) 2023-06-14
AU2021322255A1 (en) 2023-02-23
CL2023000296A1 (es) 2023-08-25
US20260021077A1 (en) 2026-01-22
AU2021322255A8 (en) 2023-03-30
US20240041840A1 (en) 2024-02-08
IL300357A (en) 2023-04-01
KR20230067604A (ko) 2023-05-16
WO2022031956A1 (en) 2022-02-10
CN116419746A (zh) 2023-07-11
JP2023538278A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
MX2024000049A (es) Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
PT1689404E (pt) Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
MX2023006720A (es) Tratamiento con ciclobenzaprina para fibromialgia.
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
Rodda et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MX2024007010A (es) Pirimidinas y metodos para su uso.
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.